journal Parkinson disease xx 20xx x xx 
 DOI 10.3233/jpd-240075 
 ios Press 
 correct proof 
 1 
 Research Article 
 Localized Pantothenic Acid vitamin b5 
 reduction present 
 Dementia Lewy Bodies Brain 
 Melissa scholeﬁelda,∗ Stephanie J. Churcha Jingshu Xub Stefano Patassinib 
 Garth J.S. Coopera b 
 adivision Cardiovascular Sciences School Medical Sciences Faculty Biology Medicine Health 
 University Manchester Manchester UK 
 bSchool Biological Sciences Faculty Science University Auckland Private Bag Auckland New Zealand 
 Accepted 10 April 2024 
 Abstract 
 Background localized pantothenic acid deﬁciencie observe neurodegenerative disease 
 Alzheimer disease ad Parkinson disease dementia pdd Huntington disease hd indicate downstream 
 energetic pathway perturbation study perform deﬁciencie occur 
 dementia lewy body dlb brain pattern dysregulation 
 objective firstly study aim quantify pantothenic acid level region brain order determine 
 localization pantothenic acid dysregulation dlb secondly localization pantothenic acid alteration 
 compare previously ad pdd hd brain 
 method pantothenic acid level determine 20 individual dlb 19 control ultra-high performance 
 liquid chromatography-tandem mass spectrometry uhplc ms/ms brain region case control difference 
 determine nonparametric mann Whitney U test calculation s-value risk ratio e-value effect 
 size result compare previously obtain dlb ad hd 
 result pantothenic acid level signiﬁcantly decrease investigate brain region pon substantia 
 nigra motor cortex middle temporal gyrus primary visual cortex hippocampus level pantothenic acid dys- 
 regulation similar ad brain pantothenic acid decrease motor cortex middle 
 temporal gyrus primary visual cortex hippocampus dlb appear differ neurodegenerative disease 
 pantothenic acid dysregulation cerebellum 
 conclusion pantothenic acid deﬁciency appear share mechanism neurodegenerative disease 
 difference localization dysregulation contribute differ clinical pathway observe 
 condition 
 ∗correspondence Melissa Scholeﬁeld division cardio- 
 vascular Sciences School Medical Sciences Faculty Biology 
 Medicine Health University Manchester Manchester 
 M13 9nt UK e-mail melissa.scholeﬁeld@manchester.ac.uk 
 issn 1877 7171 © 2024 author publish ios Press Open Access article distribute term 
 Creative Commons Attribution-NonCommercial License cc by-nc 4.0 
 2 
 M. Scholeﬁeld et al. Pantothenic Acid Deﬁciency DLB Brain 
 plain Language Summary 
 Decreases molecule call pantothenic acid know vitamin b5 observe area 
 brain multiple dementia disease include Alzheimer disease Parkinson disease dementia Huntington disease 
 unknown change occur dementia disease dementia lewy body 
 show symptom molecular change condition study perform order 
 determine change pantothenic acid occur dementia lewy body brain 
 methodology call liquid chromatography mass spectrometry able measure pantothenic acid level highly 
 precise manner brain tissue find region dementia lewy body brain decrease 
 pantothenic acid include involve movement substantia nigra motor cortex region 
 associate cognition memory hippocampus look similar pattern change 
 see alzheimer disease possible change contribute progression dementia lewy body 
 study need perform determine point change happen disease 
 contribute development symptom 
 Keywords pantothenic acid vitamin b5 dementia lewy body mass spectrometry metabolomic uhplc ms/ms 
 lewy body dementia 
 INTRODUCTION 
 Dementia lewy body dlb neurode- 
 generative disease clinically diagnose 
 presence parkinsonian motor dysfunction present- 
 ing year follow onset cognitive 
 decline contrast Parkinson disease 
 dementia pdd motor dysfunction pre- 
 cede cognitive decline 1 present relative 
 onset cognitive motor dysfunction pri- 
 mary mean distinguish dlb pdd 
 clinical neuropathological pre- 
 sentation similar neuropathologically 
 condition present extensive dopaminergic 
 neuronal loss primarily substantia nigra 
 par compacta snpc spread 
 brain disease progress neuronal loss 
 accompany extensive deposition -synuclein- 
 contain lewy body dlb present 
 somewhat cortical deposition lewy 
 body 2 case end- 
 stage neuropathological presentation 
 disease make difﬁcult distinguish 
 postmortem 
 complicate matter dlb show 
 similarity common neurodegen- 
 erative disease alzheimer disease ad prior 
 onset motor dysfunction dlb 
 difﬁcult distinguish ad clinic 
 support clinical criterion include presence 
 rem-behavior sleep disorder rbd restless leg 
 syndrome hallucination 1 
 present neuropathologically ad 
 characterize primarily cholinergic neuronal loss 
 hippocampus hp accompany mis- 
 fold amyloid- tau inclusion 
 third dlb case present amyloid- 
  tau pathology postmortem 3 
 half ad case -synuclein pathology 
 4 deﬁnitive diagnosis remain challenge 
 suggest half dementia case 
 fact case mixed dementia 5 fur- 
 ther complicate diagnosis cause issue 
 admit dlb patient correct treatment 
 pathway therapeutic safe use 
 case pdd ad typical tradi- 
 tional antipsychotic harmful administer 
 individual dlb 6 
 issue raise importance identi- 
 fye additional clinical neuropathological criterion 
 able distinguish dlb 
 similar neurodegenerative condition 
 identify mechanistic pathway 
 involve differ clinical presentation 
 dlb necessity differ therapeutic 
 pathway treatment possible cri- 
 terion presence localized pantothenic 
 acid aka vitamin b5 deﬁciencie brain 
 individual different neurodegenerative dis- 
 ease pantothenic acid essential vitamin 
 human body essential synthesis coen- 
 zyme (coa)—a molecule play essential vital 
 role metabolic process include neu- 
 rotransmitter synthesis fatty acid metabolism 
 bioenergetic pathway citric acid cycle 
 7 previous study perform lab 
 M. Scholeﬁeld et al. Pantothenic Acid Deﬁciency DLB Brain 
 3 
 directly comparable methodology identiﬁed 
 localized decrease sn medulla med 
 ponsofthepddbrain[8],inthemotorcortex(mcx 
 primary visual cortex pvc hp middle temporal 
 gyrus mtg cingulate gyrus cg ad 
 brain 9 hp sn putaman 
 globus pallidus gp middle frontal gyrus mfg 
 entorhinal cortex ent Huntington dis- 
 ease hd brain [10]—with cerebellum cb 
 region observe alter 
 condition dysregulation pantothenic 
 acid level indicate presence localized 
 deﬁciencie downstream pathway par- 
 ticular energy production pathway contribute 
 pathogenesis disease 
 aim study carry simi- 
 lar investigation multiple region dlb 
 brain method order identify 
 pantothenic acid alteration present 
 dlb brain change localized 
 pattern pantothenic alteration 
 dlb brain similar different observe 
 ad pdd hd study represent ﬁrst 
 investigation pantothenic acid level 
 dlb brain 
 method 
 study involve human participant 
 review 
 
 approve 
 
 Manchester 
 REC 
 09/h0906/52 + 5 NZ Neurological Foundation 
 Douglas Human Brain Bank UK MRC Brain 
 Bank Network patients/participant provide 
 write informed consent participate 
 study high value additional 
 statistical test perform risk ratio e- 
 value s-value effect size indicate 
 reliability current study ﬁnding 
 acquiring tissue pantothenic acid 
 quantiﬁcation 
 purpose study brain tissue 
 region include cerebellum level 
 dentate nucleus cb motor cortex mcx primary 
 visual cortex pvc hippocampus hp pon ante- 
 rior cingulate gyrus cg medulla med substantia 
 nigra sn putaman middle temporal 
 gyrus mtg obtain 20 conﬁrme case 
 dlb 19 dementia-free control 
 Sepulveda Harvard brain bank NIH 
 neurobiobank network brain region select 
 base criterion 1 coverage region 
 typically high level neurodegeneration 
 moderate low neuronal loss 
 protein deposition order ascertain pan- 
 tothenic acid alteration match typical pattern 
 neurodegeneration dlb 2 coverage 
 region previously assess ad 
 PDD hd order able perform direct 
 regional comparison 
 patient datum available brain bank 
 collect record include age death sex 
 postmortem delay pmd -synuclein Braak stage 
 dlb subtype comorbiditie Supplementary 
 Material individual patient datum case 
 control match closely possible 
 criterion individual region pos- 
 sible pmd keep 24 hour accordance 
 previous study conduct lab 
 pantothenic acid level find change 
 rat cortex cerebellum period 
 24 hour 11 
 diagnosis dlb case 
 case control diagnose refer- 
 ring neuropathologist Sepulveda Harvard 
 brain bank NIH neurobiobank frame- 
 work dlb case receive clinical diagnosis 
 dlb lifetime accord dlb 
 Consortium Criteria 1 neuropathological 
 diagnosis lewy body dementia lbd accord- 
 ing McKeith criterion 1 
 stage accord -synuclein Braak stage 
 DLB case subtype brainstem-predominant 
 amygdala-predominant olfactory bulb limbic 
 diffuse/cortical dlb accord previously 
 deﬁned criterion 1 short subtype 
 deﬁnedbyaccordingtothedistributionofa-synuclein 
 pathology brain 
 follow pattern traditional Braak stag- 
 ing 12 mixed dementia dlb/ad case 
 identiﬁed accord presence ad neu- 
 ropathology 13 Braak tau score include 
 possible control diagnose 
 form dementia lifetime show 
 -synuclein pathology tau Braak score 
 < 2 
 pantothenic acid quantiﬁcation 
 pantothenic acid quantiﬁcation perform 
 
 previously 
 validate 
 method 
 14 
 
 4 
 M. Scholeﬁeld et al. Pantothenic Acid Deﬁciency DLB Brain 
 short sample extract 50 50 v/v 
 methanol chloroform 
 contain 
 known 
 con- 
 centration 
 
 heavy-labelled 
 pantothenic 
 acid 
 standard 
 vitamin 
 b5 
 di--alanine-13c6,15n2 
 sigma-aldrich Missouri USA correct 
 intra- inter-run variability methanol chloroform 
 internal standard blank prepare sample 
 lyse TissueLyser batch bead homogeniser 
 Qiagen Manchester UK carbamide bead 
 lc ms grade water add lysed sample 
 centrifugation 2400 × g separate polar 
 non-polar phase polar methanol phase 
 transfer fresh tube dry overnight 
 speedvac centrifugal concentrator savant 
 Speedvac Thermo Scientiﬁc UK 
 follow drying 0.1 formic acid add 
 sample blank solution trans- 
 ferred 300 l autosampler vial Thermo Fisher 
 Scientiﬁc Massachusetts USA blank con- 
 taine 0.1 formic acid prepare 
 interleave uhplc ms/ms run 
 Standard solution contain heavy-labelled 
 pantothenic acid internal standard vitamin b5 di-- 
 alanine-13c6,15n2 calcium salt ≥98 atom% ≥97 
 cp 705837 sigma-aldrich unlabelle pan- 
 tothenic acid external standard d-pantothenic acid 
 hemicalcium salt ≥98.0 1210 sigma-aldrich 
 0.1 formic acid prepare 300 l autosam- 
 pler vial contain concentration 0–5000 nm 
 unlabelled 500 nm labelled pantothenic acid 
 create standard curve 
 analysis determine concen- 
 tration pantothenic acid sample 
 qc contain 20 200 2000 nm unlabelled 
 500 nm labelled pantothenic acid standard 
 0.1 formic acid prepare inter- 
 leave run account intra-run 
 variability 
 pantothenic acid quantiﬁcation perform 
 Accela uhplc ms Thermo Fisher Scientiﬁc 
 Hypersil Gold aq column diameter 
 2.1 mm length 100 mm particle size 
 1.9 m reverse phase mode Thermo Fisher Sci- 
 entiﬁc 25302 101130 0.5 m pre-column ﬁlter 
 Thermo Fisher Scientiﬁc 22016 column 
 maintain 25 ◦ c nitrogen carrier gas 
 ﬂow rate 300 l/min electrospray ioniza- 
 tion source argon collision gas 
 region analyze run randomization 
 case control inter-run intra-run vari- 
 ability control addition know 
 concentration spiked internal standard 
 uhplc-ms/ms datum analysis 
 Peaks identiﬁed base expect reten- 
 tion time rt base comparison rt 
 spike pantothenic acid label internal stan- 
 dard peak manually check ensure correct 
 identiﬁcation software standard 
 accept show difference < 15 
 6/10 standard require acceptance stan- 
 dard curve qc show difference > 20 
 exclude 2/3 successful qc require 
 set run accept 
 concentration pantothenic acid sample 
 determine base standard curve con- 
 centration correct sample wet-weight 
 case-control difference analyze GraphPad Prism 
 v8.1.2 Prism La Jolla non-parametric 
 mann Whitney U test small sam- 
 ple size p-value < 0.05 consider signiﬁcant 
 Shannon diversity index s-value aka surprisal 
 score calculate take negative 
 base 2 log p-value conﬁdence interval 
 calculate follow equation 
 CI = se ∗z(0.95 
 1 
 se = standard error z(0.95 = 
 z-score correspond conﬁdence level 
 0.95 mann Whitney U calculation perform 
 graphpad v8.1.2 Prism La Jolla p- 
 value < 0.05 consider signiﬁcant 
 order determine statistical power 
 datum obtain post hoc power analysis 
 perform statistical power deter- 
 mine region p < 0.05 p < 0.01 
 ClinCalc Post Hoc Power Calculator 
 clincalc llc Chicago il usa available 
 https://clincalc.com/stats/power.aspx statistical 
 power > 80 consider good addition 
 minimum number sample require 
 conﬁdently determine case control difference 
 signiﬁcance level p < 0.05 p < 0.01 
 calculate ClinCalc Sample Size calcula- 
 tor clincalc llc Chicago il usa available 
 https://clincalc.com/stats/samplesize.aspx 
 sensitivity analysis 
 order assess interpretation 
 datum obtain current study appropriate 
 robust sensitivity analysis perform 
 signiﬁcant p < 0.05 case control difference metal 
 level individual run mean value 
 M. Scholeﬁeld et al. Pantothenic Acid Deﬁciency DLB Brain 
 5 
 replicate run take risk ratio 
 rr e-value effect size determine 
 explanation give 
 risk ratio compare risk 
 health event different group case 
 compare dlb case control determine 
 follow equation 
 RR = 
 a 
 b 
  c 
 d 
  
 2 
 = number case value > 95 upper 
 CI limit control < 95 low ci limit 
 signiﬁcant decrease observe case 
 b = number case c = number control value 
 > 95 upper ci limit control < 95 low 
 ci limit signiﬁcant decrease observe 
 case d = number control risk ratio 
 > 3 consider robust case null 
 value calculation risk ratio null value 
 assign value 0.5 
 e-value calculate risk ratio 
 upper low conﬁdence limit risk 
 ratio e-value deﬁne minimum strength 
 association risk ratio scale potential 
 confounder treat- 
 ment e.g. urea level outcome e.g. 
 increase risk dlb explain away observe 
 treatment outcome association i.e. observe 
 association concentration urea 
 increase risk dlb take account 
 measure covariate include age sex 
 pmd high e-value strong con- 
 founding require nullify treatment outcome 
 association e-value calculate equa- 
 tion 3 
 e value = rr + sqrt(rr x rr–1 
 3 
 calculation e-value rr < 1 
 inverse risk ratio ﬁrst take e-value 
 calculate conﬁdence interval risk 
 ratio range conﬁdence interval cross 
 1.0 e-value determine 1.0 other- 
 wise e-value calculate accord Equation 
 5 substitute rr ci close 1.0 
 effect size describe strength rela- 
 tionship observe variable 
 indicate difference present 
 chance determination effect size 
 indicate signiﬁcantly altered p < 0.05 
 variable negligible inﬂuence out- 
 come conversely variable find 
 non-signiﬁcant(p < 0.05)intraditionalstatisticaltest- 
 ing large contribution outcome 
 occur statistical power low 
 small sample size effect size 
 determine Glass delta 
 glass′ = m1 −m2)/σ control 
 4 
 m1 = mean case value m2 = mean control 
 value σ control = standard deviation con- 
 trol group m1 m2 reverse case 
 signiﬁcant decrease glass delta 
 group sample size equal standard 
 deviation unequal effect size value 0.2–0.5 
 consider small value 0.50 0.80 
 consider medium size value 0.80 
 1.30 consider large effect size > 1.30 
 consider large 
 result 
 Cohort characteristic 
 study brain tissue obtain 10 
 region total 20 dlb case 19 con- 
 trol asnoteverydonorhadtissueavailableforevery 
 investigatedbrainregion individualnnumbersvaried 
 region Table 1 
 case control match closely pos- 
 sible sex age death pmd 
 signiﬁcant difference overall cohort 
 individual brain region sex age death 
 Table 2 pmd slightly short pmd 
 case control overall cohort Sup- 
 plementary table a2 accordance previous 
 study conduct group assess effect 
 pmd metabolite brain PMD 
 keep close 24 hour possible 
 pantothenic acid level find alter 
 period time 11 
 pantothenic acid analysis 
 pantothenic acid concentration measure 
 dlb case control region 
 brain uhplc-ms/ms investigate 
 region show signiﬁcant p < 0.05 decrease 
 case compare control Table 3 Fig. 1 
 individual value Supplementary Material b 
 include pon 29.3 vs. 32.6 m/kg p = 0.002 
 sn 47.1 vs. 58.9 m/kg p = 0.004 mcx 45.0 vs. 
 84.1 m/kg p = 0.007 mtg 29.7 vs. 47.1 m/kg 
 p = 0.02 pvc 48.6 vs. 91.5 m/kg p = 0.008 
 6 
 M. Scholeﬁeld et al. Pantothenic Acid Deﬁciency DLB Brain 
 Table 1 
 Number case control investigate region 
 hp 
 med 
 mtg 
 cg 
 pvc 
 PONS 
 MCX 
 
 sn 
 cb 
 control 
 14 
 15 
 15 
 15 
 16 
 14 
 16 
 13 
 18 
 16 
 case 
 15 
 15 
 15 
 15 
 15 
 8 
 15 
 8 
 15 
 12 
 Table 2 
 overall cohort characteristic 
 Age death y 
 sex male 
 pmd h 
 control n = 19 
 73.6 65–85 
 57.9 
 18.4 8.1–29.1 
 case n = 20 
 74.1 65–85 
 60.0 
 14.7 (8.0–22.6)∗ 
 Table show datum age pmd mean range pmd postmortem delay ∗p < 0.05 
 table 3 
 pantothenic acid concentration dlb case control 
 Region 
 control 
 m/kg 
 case 
 m/kg 
 fold-change 
 p 
 s-value 
 e-value 
 rr 
 RR ci 
 e-value 
 Effect 
 Size 
 PONS 
 32.6 ± 15.4 
 19.7–45.4 
 29.3 ± 7.5 
 23.0–35.5 
 0.9 
 0.002 
 9.3 
 8.8 
 4.7 
 1.7–12.7 
 2.8 
 –1.2 
 cb 
 69.1 ± 31.7 
 49.9–88.3 
 47.1 ± 21.3 
 32.8–61.4 
 0.7 
 0.1 
 3.1 
 2.9 
 1.8 
 0.7–4.7 
 1.0 
 –0.7 
 sn 
 58.9 ± 25.5 
 42.7–75.0 
 29.7 ± 11.8 
 21.8–37.6 
 0.5 
 0.004 
 8.0 
 4.9 
 2.7 
 1.2–6.2 
 1.7 
 –1.2 
 mcx 
 84.1 ± 42.0 
 61.7–106.5 
 45.0 ± 21.5 
 32.1–58.0 
 0.5 
 0.007 
 8.1 
 4.9 
 2.7 
 1.3–5.8 
 1.8 
 –0.9 
 cg 
 35.3 ± 16.2 
 26.3–44.3 
 25.2 ± 8.6 
 20.2–30.2 
 0.7 
 0.09 
 4.5 
 2.2 
 1.4 
 0.7–3.1 
 1.0 
 –0.6 
 mtg 
 47.1 ± 22.9 
 34.5–59.8 
 29.7 ± 18.9 
 13.9–24.3 
 0.6 
 0.02 
 6.0 
 3.4 
 2.0 
 0.9–4.5 
 1.0 
 –0.8 
 med 
 27.3 ± 13.7 
 19.4–35.2 
 20.4 ± 10.1 
 14.5–26.2 
 0.8 
 0.2 
 2.3 
 1.6 
 1.2 
 0.5–2.7 
 1.0 
 –0.5 
 pvc 
 91.5 ± 46.5 
 65.7–117.2 
 48.6 ± 20.2 
 36.4–60.8 
 0.5 
 0.008 
 7.9 
 3.3 
 1.9 
 0.97–3.8 
 1.0 
 –0.9 
 
 140.6 ± 89.5 
 86.5–194.7 
 81.8 ± 40.9 
 58.2–105.3 
 0.6 
 0.09 
 4.5 
 3.1 
 1.9 
 0.7–4.7 
 1.0 
 –0.7 
 hp 
 91.5 ± 28.7 
 73.3–109.8 
 49.4 ± 17.8 
 39.1–59.7 
 0.5 
 < 0.0001 
 11.5 
 3.5 
 2.1 
 1.02–4.2 
 1.2 
 –1.5 
 Table show mean pantothenic acid concentration 95 conﬁdence interval m/kg case control difference determine 
 Mann Whitney U test p < 0.05 consider signiﬁcant fold-change case compare control Supplementary Material b 
 individual datum rr risk ratio 
 hp 49.4 vs. 91.5 m/kg p < 0.0001 determine 
 non-parametric mann Whitney U test statis- 
 tically signiﬁcant difference find cb 
 cg med 
 determine pantothenic acid level 
 change present different brain region 
 measure statistical signiﬁcance con- 
 sidere effect size e-value 
 effect size range medium large 
 region statistically signiﬁcant difference 
 observe base p-value range 
 –0.5 med high –1.5 hp 
 statistically signiﬁcant region effect size 
 large 0.8–1.3 large > 1.3 e-value range 
 1.6 med 8.8 pon low 
 e-value statistically signiﬁcant region 3.3 
 pvc risk ratio range 1.4 cg 
 4.7 pon statistically signiﬁcant region 
 risk ratio range 1.9 pvc 4.7 
 pon reach robust value > 3 pon 
 post hoc power analysis perform 
 investigate brain region determine statistical 
 power obtain datum Supplementary Table 
 a10 statistical power ≥80 consider 
 good region show p < 0.05 statistical 
 power ≥80 hp show high 
 power 99.3 follow pon 98.9 
 sn 94.6 mcx pvc 89.9 
 M. Scholeﬁeld et al. Pantothenic Acid Deﬁciency DLB Brain 
 7 
 Table 4 
 pantothenic acid fold-change pdd ad hd 
 Region 
 fold-change dlb 
 fold-change PDD 8 
 fold-change ad 9 
 Fold-Change hd 10 
 cb 
 0.7 
 0.6 
 0.5 
 0.6 
 MCX 
 0.5 
 0.8 
 0.3 
 0.6 
 pvc 
 0.5 
 0.9 
 0.4 
 0.5 
 hp 
 0.5 
 0.9 
 0.5 
 0.5 
 sn 
 0.5 
 0.6 
 
 0.6 
 MTG 
 0.6 
 0.9 
 0.5 
 0.6 
 med 
 0.7 
 0.6 
 
 
 cg 
 0.7 
 0.8 
 0.5 
 0.5 
 PONS 
 0.9 
 0.7 
 
 
 
 0.6 
 
 
 0.5 
 gp 
 
 
 
 0.4 
 mfg 
 
 
 
 0.6 
 ent 
 
 
 0.4 
 0.6 
 Table show case-control fold-change urea cb cerebellum mcx motor cortex pvc primary visual cortex 
 hp hippocampus sn substantia nigra mtg middle temporal gyrus med medulla cg cingulate gyrus 
 putaman gp globus pallidus mfg middle frontal gyrus ent entorhinal cortex signiﬁcant intra-cohort case control 
 fold-change highlight bold 
 comparison pdd ad hd 
 pantothenic acid level measure 
 lab pdd ad hd brain 
 methodology employ current study 
 result investigation 
 compare directly region 
 brain Table 4 Fig. 2 dlb result 
 directly compare region PDD brain 
 cb mcx pvc hp sn mtg med cg 
 pon table 4 region ad brain cb 
 MCX pvc hp mtg cg seven region 
 hd brain cb mcx pvc hp sn mtg 
 cg result comparable con- 
 dition region brain cb mcx pvc 
 hp mtg cg characteristic ad 
 PDD hd cohort find Supplementary 
 Tables a3–9 
 dlb ﬁrst disease sig- 
 niﬁcant case control difference pantothenic acid 
 cb indicate relative protection 
 region useful distinguish dlb 
 neurodegenerative disease term 
 share alteration dlb look similar 
 ad show signiﬁcant decrease pan- 
 tothenic acid region mcx pvc hp 
 mtg result reinforce neuropatholog- 
 ical similarity observe 
 condition 
 extent pantothenic acid deﬁciency 
 affect region appear similar 
 region disease average fold-change 
 0.5–0.6 disease region 
 show 0.3 ad mcx 0.9 
 dlb pon extensive decrease 
 dlb pdd hd signiﬁcant decrease 
 sn indicate vulnerability region 
 neurodegenerative disease associate motor 
 dysfunction region investigate 
 ad unknown region spare 
 dementia disease associate 
 motor symptom dlb hd ad pan- 
 tothenic acid decrease hp region 
 appear share PDD asso- 
 ciate differ level cognitive decline 
 condition dlb show share alter- 
 ation hd pdd despite extensive 
 clinical neuropathological similarity 
 
 DISCUSSION 
 study represent ﬁrst multi-regional inves- 
 tigation pantothenic level dlb brain 
 observingstatisticallysigniﬁcantdecreasesacrosssix 
 investigate region pattern pan- 
 tothenic acid alteration appear similar 
 observe ad similarity PDD 
 hd region affect include 
 high typical level neurodegeneration lewy 
 body deposition dlb sn hp 
 MCX relatively spare region cb 
 med show alteration unlike 
 neurodegenerative disease cb appear 
 protect pantothenic acid alteration dlb 
 decrease substantia nigra appear 
 common observation condition associate 
 motor dysfunction dlb pdd hd 
 8 
 M. Scholeﬁeld et al. Pantothenic Acid Deﬁciency DLB Brain 
 pantothenic acid 
 pantothenic acid essential b vitamin 
 act precursor coa vital component 
 vast number metabolic pathway include 
 fatty acid synthesis subsequent regulation 
 excess glucose level energy production 
 citric acid cycle antioxidation lipid carbohydrate 
 amino acid metabolism protein synthesis 
 post-translation protein modiﬁcation oth- 
 er 7 overall coa serve cofactor 
 4 known enzyme alteration 
 coa level multitude down- 
 stream metabolic effect effect 
 observe ad brain widespread perturba- 
 tion coa-modulated enzyme enzyme 
 complex pyruvate dehydrogenase complex isoc- 
 itrate dehydrogenase 2-oxoglutarate dehydroge- 
 nase complex succinyl-coa synthetase 
 report 15 coa role protein modiﬁcation 
 antioxidation play key role tauopathie 
 ad dlb coalation tau protein 
 ad brain sample observe protect 
 h2o2-induced dimerization tau 16 loss 
 coa result pantothenic acid deﬁciency 
 lead loss protective mechanism 
 increase level coa suggest pro- 
 tect general cognitive decline aging 
 brain 17 
 pantothenic acid generally obtain 
 diet available wide variety food 
 source occur particularly high level 
 egg beef chicken vegetable fortiﬁed 
 cereal 18 ease obtain sufﬁcient 
 amount pantothenic acid food source 5 mg 
 daily adult 19 deﬁciency rare usu- 
 ally present individual severe general 
 malnutrition mutation pantothen- 
 ate kinase 2 pank2 gene chromosome 20 
 result pantothenic acid deﬁciency down- 
 stream coa deﬁciency 20 mutation 
 result condition call pantothenate-kinase asso- 
 ciated neurodegeneration pkan condition 
 arise early life characterize motor dysfunc- 
 tionthateventuallyleadstoissueswithfall chewing 
 swallow 20 motor dysfunction appear 
 similar see pd/dlb psychiatric 
 disturbance occur cerebral iron accumula- 
 tion occur pkan observe 
 study pd/pdd brain 21 
 report beneﬁcial effect pan- 
 tothenic acid supplementation pkan 
 currently standard treatment pathway 
 disease 22 
 pantothenic acid neurodegenerative disease 
 despite rarity pantothenic acid deﬁciency 
 signiﬁcantly low level dietary pantothenic acid 
 intake observe individual pd 
 comparison healthy individual pan- 
 tothenic acid level display clinical importance 
 predict incidence pd 23 
 study updrs score negatively corre- 
 latedwithpantothenicacidintake assuch decrease 
 dietary pantothenic acid intake associate 
 pd incidence severity pantothenic 
 acid intake associate amyloid- 
 burden individual mild cognitive impair- 
 ment mci indicate potential link ad 
 24 despite lack outright pantothenic 
 acid deﬁciency supplementation potential 
 therapeutic option treatment neurode- 
 generative disease 
 author knowledge investi- 
 gation absolute cerebral pantothenic acid level 
 neurodegenerative disease 
 study report decrease level 
 frontal cortex individual ad identify- 
 ing pantothenate coa biosynthesis altered 
 pathway ad brain 25 conversely indi- 
 vidual mci cerebral pantothenic acid level 
 appear positively correlate amyloid- 
 deposition brain 6 association 
 observe investigate vitamin indi- 
 vidual regional analysis find association 
 frontal parietal temporal cortex 
 relationshipdidnotreachsigniﬁcanceinthecingulate 
 gyrus discrepancy ﬁnding 
 analysis ad brain reﬂect 
 regional difference pantothenic acid dysregula- 
 tion frontal parietal temporal cortex 
 investigate study 
 result conﬂict paglia et al. 
 frontal cortex mention 25 furthermore 
 study ˇ 
 Cuperlovi ´ 
 c-culf et al. observe metabolic 
 network alteration neocortex dlb patient 
 involve pantothenate despite observe sig- 
 niﬁcant difference pantothenate concentration 
 dlb case control 26 give support 
 role pantothenic acid dlb brain 
 non-cns disturbance pantothenic acid 
 related pathway observe neu- 
 rodegenerative disease instance pantothenate 
 M. Scholeﬁeld et al. Pantothenic Acid Deﬁciency DLB Brain 
 9 
 coa biosynthesis find dis- 
 turbe lc ms metabolomic analysis pd 
 healthy plasma serum sample decrease 
 pantothenic acid level observe early 
 stage pd 27 28 presence pantothenic 
 alteration pd gut dispute 
 study show change stool sample lev- 
 el 29 show decrease 30 
 study show positive associ- 
 ation fecal pantothenic acid level 
 non-motor symptom pd 31 increase 
 decrease serum pantothenic acid level 
 report study 50 individual non-speciﬁc 
 dementia 32 pantothenate coa biosyn- 
 thesis pathway dysregulation report 
 multi-omic investigation ad brain blood 
 cerebrospinal ﬂuid 33 pantothenic acid 
 disturbance wide multi-system issue 
 affect brain neurodegenerative 
 disease administration 
 pantothenic acid supplementation straightfor- 
 ward viable option therapeutic trial 
 localization pantothenic acid deﬁciency 
 current study pantothenic acid observe 
 decrease region pon sn mcx 
 mtg pvc hp region broadly 
 divide functional group over- 
 lap group associate cognitive 
 function hp mtg associate motor 
 function sn mcx pons associate 
 visual processing mtg pvc suggest 
 pantothenic acid play mechanistic role 
 aspect dlb include cognitive 
 decline motor dysfunction high prevalence 
 visual hallucination observe disease 
 conversely pdd affect region pri- 
 marilythoseinvolvedinmotordysfunction include 
 sn med pon differ local- 
 ization pantothenic acid deﬁciency account 
 difference prevalence onset motor 
 cognitive symptom dlb pdd 
 ad majority affect region 
 associate cognitive function hp 
 mtg ent cg mcx pvc 
 affect sn med pon 
 investigate ad presence pan- 
 tothenic acid dysregulation region remain 
 unknown ad region investigate 
 find affect reﬂect 
 overall atrophy observe late-stage ad hd 
 regionsinvolvedinbothcognitiveandmotordysfunc- 
 tion affect sparing pvc 
 suggest difference pantothenic acid 
 dysregulation localization reﬂect differ 
 mechanistic process occur neurode- 
 generative disease 
 strikingly unlike pdd ad hd 
 cerebellum change pantothenic acid 
 level dlb put cb forward partic- 
 ularly key brain region differentiation dlb 
 neurodegenerative disease 
 lack change see PDD pvc 
 hallucination likely occur dlb 
 pantothenic acid level aid deﬁnitive post- 
 mortem diagnosis dlb future study 
 condition prioritize brain region 
 investigate mechanistic pathway contribute 
 differ clinical progression condi- 
 tion 
 Strengths limitation 
 current study strength lim- 
 itation consider discuss 
 potential implication datum obtain 
 term strength ﬁrst study 
 author knowledge multi-regional fully 
 quantitative study pantothenic acid level 
 perform dlb carry 
 validate methodology 
 quantify pantothenic acid level ad pdd 
 hd allow direct region-to-region compar- 
 ison improve methodology large 
 cohort obtained—15 vs. 15 pre- 
 vious sample size 9 vs. 9—in order improve 
 conﬁdenceintheresultsobtained aswithmanybrain 
 tissue study sample size fairly 
 low consider assess 
 study ﬁnding particular region 
 observe effect size large reach- 
 ing statistical signiﬁcance beneﬁt 
 investigation large cohort 
 study limitation post- 
 mortem tissue study possible determine 
 basis datum pantothenic acid 
 changesareacauseoraresultofpathologicalchange 
 dlb pantothenic acid level deter- 
 mine vivo brain current method 
 investigation peripheral level 
 csf plasma necessary determine 
 temporality alteration 
 possible event cerebral pantothenic 
 10 
 M. Scholeﬁeld et al. Pantothenic Acid Deﬁciency DLB Brain 
 acid change reﬂecte periphery 
 evidence case 
 observe study pd plasma serum 
 27 28 determine 
 dlb assess peripheral pantothenic acid 
 level longitudinal cohort intuitive 
 informative investigation follow cur- 
 rent study 
 limitation lack additional 
 datum cohort study information 
 -synuclein Braak stage duration 
 disease additional factor 
 useful evaluation study datum unfor- 
 tunately datum available brain 
 bank datum available request sup- 
 plying brain bank available Supplementary 
 Material a. prevent evaluation pan- 
 tothenic acid level relation -synuclein Braak 
 stage informative repeat study 
 large cohort representation -synuclein 
 Braak stage order determine correlation 
 cerebral pantothenic acid level 
 conclusion 
 pantothenic acid deﬁciency appear share 
 perturbation brain dlb 
 ad pdd hd despite clinical neu- 
 ropathological difference difference 
 account difference localization 
 pantothenic acid alteration region brain 
 associate motor cognitive function 
 visual processing affect dlb brain 
 pantothenic acid alteration inves- 
 tigate potential mechanistic role 
 disease look temporal alteration periph- 
 eral pantothenic acid level close attention 
 pay region brain pvc 
 cb appear able well differentiate 
 dlb similar neurodegenerative disease 
 future study dlb brain 
 AUTHOR contributions 
 ms conceptualization data curation formal 
 analysis investigation methodology project admin- 
 istration validation visualization write original 
 draft review editing jx sc saph stpa 
 Investigation methodology gjsc conceptual- 
 ization funding acquisition resource supervision 
 writing review editing ms gjsc veri- 
 ﬁed underlying datum manuscript 
 Fig. 1 pantothenic acid concentration dlb case con- 
 trol figure show mean urea concentration ± 95 conﬁdence 
 interval m/kg case control difference determine 
 Mann Whitney U test cb cerebellum sn substantia 
 nigra MCX motor cortex cg cingulate gyrus med Medulla 
 MTG middle temporal gyrus pvc primary visual cortex 
 Putamen HP Hippocampus 
 author read approve ﬁnal version 
 manuscript 
 acknowledgments 
 thank Cynthia Tse University 
 Auckland help obtain brain tissue 
 sample study 
 nih DLB Cohort human dlb tissue 
 obtain NIH Neurobiobank 
 Harvard Brain Tissue Resource Centre sepul- 
 veda Research Corporation thank bank 
 donor supply tissue 
 nih PDD Cohort human PDD tissue 
 obtain NIH Neurobiobank 
 University Miami Brain Endowment Bank 
 thank bank donor supply 
 tissue 
 Auckland ad hd cohort thank 
 family patient alzheimer disease 
 generously support research 
 donation brain tissue nz neurological foun- 
 dation Douglas Human Brain Bank Centre 
 Brain Research Faculty Medical Health 
 FUNDING 
 work fund grant endo- 
 core Research Associates New Zealand 60147 
 Maurice Phyllis Paykel Trust New Zealand 
 3627036 travel funding jx Lottery 
 Health New Zealand 3626585 3702766 mau- 
 rice Wilkins Centre Molecular Biodiscovery 
 M. Scholeﬁeld et al. Pantothenic Acid Deﬁciency DLB Brain 
 11 
 Fig. 2 comparison pantothenic acid alteration dlb pdd ad hd brain blue region indicate decrease pantothenic 
 acid grey region indicate change pantothenic acid grey dotted shading indicate region investigate condition 
 cb cerebellum cg Cingulate Gyrus ent Entorhinal Cortex hp hippocampus med Medulla MCX Motor Cortex mfg Middle 
 frontal gyrus mtg Middle Temporal Gyrus Putamen pvc primary visual cortex sn Substantia Nigra 
 New Zealand Tertiary Education Commission 9341- 
 3622506 Doctoral Scholarship JX Lee 
 Trust New Zealand University Auckland 
 Doctoral Student PReSS funding JXU058 oak- 
 ley Mental Health Research Foundation 3456030 
 3627092 3701339 3703253 3702870 min- 
 istry business Innovation Employment New 
 Zealand uoax0815 Neurological Foundation 
 New Zealand Medical Research Council UK 
 mr/l010445/1 mr/l011093/1 Alzheimer 
 research UK aruk-ppg2014b-7 univer- 
 sity Manchester cmft Northwest 
 Regional Development Agency combined 
 programme grant cadet facilitate 
 Manchester Biomedical Research Centre 
 great Manchester Comprehensive Local Research 
 Network 
 conflict interest 
 author conﬂict interest report 
 data availability 
 raw datum individual run include 
 Supplementary Material b concentration give 
 mm/kg value give mean average stan- 
 dard deviation conﬁdence interval Welch t-test 
 Mann-Whitney U test result wet weight sample 
 weight give mg detail software 
 analysis include method section 
 supplementary MATERIAL 
 supplementary material available 
 electronic version article https://dx.doi.org/ 
 10.3233/jpd-240075 
 references 
 1 
 McKeith ig Boeve BF Dickson DW Halliday g Taylor 
 JP Weintraub D Aarsland D Galvin J Attems J Ballard 
 CG Bayston Beach tg Blanc F Bohnen N Bonanni L 
 Bras J Brundin p Burn D chen-plotkin Duda JE el- 
 Agnaf O Feldman H ferman tj Ffytche d Fujishiro h 
 Galasko D Goldman jg Gomperts sn graff-radford NR 
 Honig ls Iranzo Kantarci K Kaufer D Kukull W Lee 
 VMY Leverenz JB Lewis S lippa c Lunde Masellis M 
 Masliah E McLean p mollenhauer b montine tj Moreno 
 E mori e Murray M o’brien JT Orimo S postuma rb 
 Ramaswamy S Ross OA Salmon dp Singleton Taylor 
 Thomas Tiraboschi p Toledo JB Trojanowski JQ 
 Tsuang D Walker Z Yamada M Kosaka K 2017 diagno- 
 sis management dementia lewy body fourth 
 consensus report DLB Consortium neurology 89 
 88 100 
 2 
 Cabrero FR morrison EH 2022 lewy body stat- 
 Pearls internet StatPearls Publishing 
 3 
 Chin KS Yassi N Churilov L Masters CL Watson R 2020 
 Prevalence clinical association tau lewy body 
 dementia systematic review meta-analysis parkin- 
 sonism Relat Disord 80 184 193 
 4 
 Twohig D Nielsen HM 2019 alpha-synuclein patho- 
 physiology alzheimer disease mol Neurodegener 14 
 23 
 5 
 Zekry D Hauw jj gold g 2002 mixed dementia epi- 
 demiology diagnosis treatment j Geriatr Soc 50 
 1431 1438 
 6 
 Boot bp 2015 comprehensive treatment dementia 
 lewy body alzheimer Res Ther 7 45 
 7 
 Theodoulou FL Sibon OC Jackowski S Gout 2014 
 Coenzyme derivative Renaissance textbook 
 classic Biochem Soc Trans 42 1025 1032 
 8 
 Scholeﬁeld M Church SJ Xu J Patassini S Hooper NM 
 Unwin RD Cooper gjs 2021 substantively lower lev- 
 el pantothenic acid vitamin b5 region 
 human brain Parkinson disease dementia metabolite 
 11 569 
 9 
 Xu J Begley p Church SJ Patassini S Hollywood KA 
 Jullig M Curtis ma Waldvogel HJ Faull RL Unwin RD 
 Cooper gj 2016 grade perturbation metabolism 
 multiple region human brain Alzheimer disease 
 Snapshot pervasive metabolic disorder biochim bio- 
 phys Acta 1862 1084 1092 
 10 
 Patassini S Begley p Xu J Church SJ Reid sj Kim 
 EH curtis ma Dragunow M Waldvogel HJ Snell RG 
 12 
 M. Scholeﬁeld et al. Pantothenic Acid Deﬁciency DLB Brain 
 Unwin RD Faull RL Cooper gj 2016 metabolite map- 
 ping reveal severe widespread perturbation multiple 
 metabolic process Huntington disease human brain 
 Biochim Biophys Acta 1862 1650 1662 
 11 
 Scholeﬁeld M Church SJ Xu J Robinson AC Gardiner NJ 
 Roncaroli F Hooper NM Unwin RD Cooper GJS 2020 
 effect alteration post-mortem delay tissue- 
 collection variable metabolite level human rat 
 brain metabolite 10 438 
 12 
 Outeiro tf Koss DJ Erskine d Walker L kurzawa-akanbi 
 M Burn D Donaghy p Morris C Taylor JP Thomas 
 Attems J McKeith 2019 Dementia lewy body 
 update outlook Mol Neurodegener 14 5 
 13 
 Braak H alafuzoff Arzberger t Kretzschmar H 
 Del Tredici K 2006 staging alzheimer disease- 
 associated neuroﬁbrillary pathology parafﬁn section 
 andimmunocytochemistry actaneuropathol112,389 404 
 14 
 Ismail N Kureishy N Church SJ Scholeﬁeld M Unwin 
 RD Xu J Patassini S Cooper GJS 2020 vitamin b5 d- 
 pantothenic acid localize myelinate structure 
 rat brain potential role cerebral vitamin b5 store 
 local myelin homeostasis Biochem Biophys Res Commun 
 522 220 225 
 15 
 Sang C Philbert SA Hartland D Unwin RD Dowsey aw 
 Xu J Cooper GJS 2022 coenzyme a-dependent tricar- 
 boxylic acid cycle enzyme decrease Alzheimer 
 disease consistent cerebral pantothenate deﬁciency 
 Aging Neurosci 14 893159 
 16 
 Lashley t Tossounian MA Costello Heaven N Wallworth 
 S peak-chew s Bradshaw Cooper JM de Silva R 
 Srai SK Malanchuk O Filonenko V Koopman MB rudi- 
 ger SGD Skehel M Gout 2021 extensive anti-coa 
 immunostaining alzheimer disease covalent mod- 
 iﬁcation tau key cellular metabolite coenzyme a. 
 Cell Neurosci 15 739425 
 17 
 Currais Huang L Goldberg J Petrascheck M Ates 
 g pinto-duarte Shokhirev MN Schubert D Maher p 
 2019 elevate acetyl-coa level reduce aspect brain 
 aging elife 8 e47866 
 18 
 Gonzalez-Lopez 
 J 
 Aliaga 
 L 
 Gonzalez-Martinez 
 
 martinez-toledo MV 2016 pantothenic acid industrial 
 Biotechnology Vitamins Biopigments antioxidant 
 Vandamme ej revuelta JL ed wiley-vch Verlag gmbh 
 Co pp 67 101 
 19 
 Food Drug Administration HHS 2016 Food labeling 
 revision Nutrition supplement Facts Labels 
 final rule Fed Regist 81 33741 33999 
 20 
 Hayﬂick SJ Jeong sy Sibon OCM 2022 pkan patho- 
 genesis treatment Mol Genet Metab 137 283 291 
 21 
 Genoud S Senior Hare DJ double kl 2020 meta- 
 analysis copper iron Parkinson disease brain 
 bioﬂuid Mov Disord 35 662 671 
 22 
 Kurian MA Hayﬂick sj 2013 pantothenate kinase- 
 associated neurodegeneration pkan pla2g6- 
 associated neurodegeneration plan review 
 major neurodegeneration brain iron accumulation 
 NBIA phenotype int rev Neurobiol 110 49 71 
 23 
 Alizadeh M Kheirouri S Keramati M 2023 dietary 
 vitamin mineral protective parkin- 
 son disease Brain Sci 13 1119 
 24 
 Lee jh ahn sy Lee HA Won KS Chang hw oh JS 
 Kim hw 2018 dietary intake pantothenic acid associ- 
 ate cerebral amyloid burden patient cognitive 
 impairment food Nutr Res 62 doi 10.29219/fnr.v62.1415 
 25 
 Paglia g Stocchero M Cacciatore S Lai S Angel p 
 Alam MT Keller M Ralser M Astarita g 2016 unbi- 
 ase metabolomic investigation alzheimer disease 
 brain point dysregulation mitochondrial aspartate 
 metabolism j Proteome Res 15 608 618 
 26 
 ˇ 
 Cuperlovi ´ 
 c-culf m Yilmaz Stewart D Surendra 
 Akyol S Vishweswaraiah S Shao X Alecu 
 nguyen-tran t McGuinness b 2021 sign Distance 
 Correlation sidco network analysis application 
 distance correlation identify metabolic network 
 disrupt dementia lewy body medrxiv 
 https://doi.org/10.1101/2021.10.16.21265003 
 preprint 
 post 19 2022 
 27 
 Shao y Li t Liu Z Wang X Xu X Li S Xu g Le W 
 2021 comprehensive metabolic proﬁling Parkinson 
 disease liquid chromatography-mass spectrometry mol 
 Neurodegener 16 4 
 28 
 Paul KC Zhang K Walker DI Sinsheimer J Yu Y Kusters 
 C Del Rosario Folle AD Keener Bronstein J Jones 
 dp ritz b 2023 untargeted serum metabolomic reveal 
 novel metabolite association disruption amino acid 
 lipid metabolism Parkinson disease mol neurode- 
 gener 18 100 
 29 
 Yan J Feng X Zhou X Zhao M Xiao h Li R Shen 
 h 2022 Identiﬁcation gut metabolite associate 
 Parkinson disease bioinformatic analysis 
 Aging Neurosci 14 927625 
 30 
 Vascellari S Palmas V Melis M Pisanu S Cusano R Uva p 
 Perra D Madau V Sarchioto M Oppo v Simola N Morelli 
 M Santoru ML Atzori L Melis M cossu g Manzin 
 2020 gut microbiota metabolome alteration associ- 
 ate Parkinson disease msystem 5 e00561 20 
 31 
 baldinif hertelj sandte thinnescc neuberger-castillo 
 L Pavelka L Betsou F Kruger R Thiele Consortium n-p 
 2020 Parkinson disease-associated alteration gut 
 microbiome predict disease-relevant change metabolic 
 function bmc biol 18 62 
 32 
 Cooper JL 2008 p3 400 biotin deﬁciency abnormal 
 pantothenic acid level dementia alzheimer Dement 4 
 t638-t639 
 33 
 Kodam p Sai Swaroop R Pradhan ss Sivaramakrishnan 
 V Vadrevu r 2023 integrated multi-omic analysis 
 Alzheimer disease show molecular signature associate 
 disease progression potential therapeutic target 
 Sci Rep 13 3695 
